Bell Investment Advisors’s ACELYRIN SLRN Stock Holding History

Bell Investment Advisors’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-18	Closed	-$184	–	1988
2023 Q3	$184	Buy	+18	New	+$382	﹤0.01%	1902

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bell Investment Advisors's SLRN Position: Q4 2023 in Review

Bell Investment Advisors sold out of ACELYRIN (SLRN) in Q4 2023, closing a stake of 18 shares — an estimated $184 sold.

Bell Investment Advisors first reported a position in SLRN in Q3 2023 and held it in 1 quarter. The position peaked at $184 in Q3 2023. 110 funds tracked by Wall St. Rank hold SLRN as of Q4 2023.

Bell Investment Advisors reported no remaining ACELYRIN position as of Q4 2023 after selling out during the quarter.
Bell Investment Advisors sold 18 ACELYRIN shares in Q4 2023, an estimated $184.
Bell Investment Advisors first reported a position in ACELYRIN in Q3 2023 and held it in 1 quarter.
Bell Investment Advisors's ACELYRIN position peaked at $184 in Q3 2023.
110 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2023.

Based on Bell Investment Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.